MVM. A. Vorobyova

M. A. Vorobyova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


M. A. Vorobyova has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Efficacy of mFOLFIRINOX chemotherapy for treatment of high-grade G3 neuroendocrine tumors and gastroenteropancreatic neuroendocrine carcinomas

    by Abidat K. Kachmasova, Ya. A. Zhulikov, E. V. Evdokimova, K. R. Gadzhieva, M. A. Vorobyova, Kh. A. Suleymanova, V. V. Delektorskaya, G. S. Emelyanova, А. А. Markovich, О. А. Martynova, et al.

    Background. Gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC) are rare tumors. Despite the differences in genetic characteristics, treatment principles for GEP-NECs are extrapolated from lung NECs. A small retrospective study demonstrated potential effectiveness of the mFOLFIRINOX regimen. Aim. To evaluate the efficacy of mFOLFIRINOX ± somatostatin analogues in treatment of inoperable or metastatic G3 Ki-67 ≥55 % GEP-NECs and neuroendocrine tumors (NETs) in a prospective cohort. Materials and methods. A prospective single-center phase II trial with the Simon’s two-stage design was conducted. The primary endpoint was disease control (DC) ≥6 months. The statistical hypothesis was that the mFOLFIRINOX regimen would increase the disease control rate from 50 % (historical control) to 70 %. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and objective response rate (ORR). In the 1st stage, 16 patients were planned for enrollment. If ≥9 patients achieved DC ≥6 months, the cohort would be expanded to 39 patients. Inclusion criteria: patients ≥18 years with histologically confirmed G3 Ki-67 ≥55 % GEP-NEC or NET, ECOG performance status 0–2. Patient enrollment took place between 2019 to February of 2024. Results. Sixteen patients were included in the study (12 men, 4 women). The most common primary tumor sites were the stomach (8 patients, 50 %) and pancreas (5 patients, 31.3 %). Large-cell NEC was diagnosed in 10 patients (62.5 %), small-cell NEC in 1 patient (6.3 %), and G3 NET in 5 patients (31.3 %). Median Ki-67 index was 70 % (range 40–95 %). Stage IV disease was diagnosed in 15 patients (93.7 %), and 1 patient (6.3 %) had unresectable gastric NEC. The liver was the most frequent site of metastases (n = 11, 68.8 %), with isolated liver involvement in 9 patients (56.3 %). ECOG performance status was 0–1 in 15 patients (93.7 %). The majority (n = 14, 87.5 %) of patients received mFOLFIRINOX as 1st line treatment. Positive expression of somatostatin receptors SSTR2A / 5 was found in 7 patients (43.7 %), who additionally received somatostatin analogues. ORR was 62.5 % (n = 10), and stable disease was observed in 37.5 % (n = 6) of patients. Disease control ≥6 months was achieved in 93.7 % of patients (n = 15). With a median follow-up of 13.2 months, median PFS was 10.8 months (95 % confidence interval 7.57–14.1). One serious adverse event (myocardial infarction) was reported. No grade V toxicity was observed. Conclusion. mFOLFIRINOX chemotherapy demonstrated promising results in treatment of G3 Ki-67 ≥55 % GEP NECs and NETs. The primary endpoint was met, and the study is ongoing.